Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy

A notable feature of immune checkpoint inhibitor (ICI) therapy in oncology patients is its association with increased frequency of immune related adverse reactions, directly associated with their unique mechanism of action. These adverse events are of great interest to rheumatologists, as not only d...

Descripción completa

Detalles Bibliográficos
Autores principales: Koulouri, Vasiliki, Karamouzis, Michalis V., Mavragani, Clio P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802194/
https://www.ncbi.nlm.nih.gov/pubmed/35128331
http://dx.doi.org/10.31138/mjr.32.4.367
_version_ 1784642627616899072
author Koulouri, Vasiliki
Karamouzis, Michalis V.
Mavragani, Clio P.
author_facet Koulouri, Vasiliki
Karamouzis, Michalis V.
Mavragani, Clio P.
author_sort Koulouri, Vasiliki
collection PubMed
description A notable feature of immune checkpoint inhibitor (ICI) therapy in oncology patients is its association with increased frequency of immune related adverse reactions, directly associated with their unique mechanism of action. These adverse events are of great interest to rheumatologists, as not only do they commonly require immunosuppressive therapeutic intervention, but can also aid in unveiling important immunopathogenetic pathways that underlie autoimmune phenomena. Herein we describe a case of psoriasiform skin lesions and polyarthritis in a patient receiving ICI for lung cancer.
format Online
Article
Text
id pubmed-8802194
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Mediterranean Journal of Rheumatology (MJR)
record_format MEDLINE/PubMed
spelling pubmed-88021942022-02-04 Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy Koulouri, Vasiliki Karamouzis, Michalis V. Mavragani, Clio P. Mediterr J Rheumatol Case Report A notable feature of immune checkpoint inhibitor (ICI) therapy in oncology patients is its association with increased frequency of immune related adverse reactions, directly associated with their unique mechanism of action. These adverse events are of great interest to rheumatologists, as not only do they commonly require immunosuppressive therapeutic intervention, but can also aid in unveiling important immunopathogenetic pathways that underlie autoimmune phenomena. Herein we describe a case of psoriasiform skin lesions and polyarthritis in a patient receiving ICI for lung cancer. The Mediterranean Journal of Rheumatology (MJR) 2021-12-27 /pmc/articles/PMC8802194/ /pubmed/35128331 http://dx.doi.org/10.31138/mjr.32.4.367 Text en © 2021 The Mediterranean Journal of Rheumatology (MJR) https://creativecommons.org/licenses/by/4.0/This work is licensed under and Creative Commons Attribution-NonCommercial 4.0 International License.
spellingShingle Case Report
Koulouri, Vasiliki
Karamouzis, Michalis V.
Mavragani, Clio P.
Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy
title Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy
title_full Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy
title_fullStr Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy
title_full_unstemmed Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy
title_short Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy
title_sort polyarthritis and psoriasiform skin lesions following pembrolizumab therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802194/
https://www.ncbi.nlm.nih.gov/pubmed/35128331
http://dx.doi.org/10.31138/mjr.32.4.367
work_keys_str_mv AT koulourivasiliki polyarthritisandpsoriasiformskinlesionsfollowingpembrolizumabtherapy
AT karamouzismichalisv polyarthritisandpsoriasiformskinlesionsfollowingpembrolizumabtherapy
AT mavraganicliop polyarthritisandpsoriasiformskinlesionsfollowingpembrolizumabtherapy

Ejemplares similares